

## IRLAB's nomination committee proposes Martin Nicklasson as new board member and provides their proposal

IRLAB (Nasdaq Stockholm: IRLAB A) announced today that the nomination committee has provided their proposal and motivated opinion ahead of the annual general meeting 2021. Martin Nicklasson is proposed as a new board member. Martin Nicklasson has extensive experience from the international pharmaceutical industry, primarily from executive positions within AstraZeneca, Pharmacia, Biovitrum and Sobi as well as a board member in several life science companies.

In addition to the nomination of Martin Nicklasson as a board member, the nomination committee proposes re-election of Gunnar Olsson as Chair of the board, Carola Lemne as vice Chair and Lars Adlersson, Rein Piir and Lena Torlegård as board members. Eva Lindgren has declined re-election. The nomination committee further proposes re-election of the auditing firm Öhrlings PriceWaterhouseCoopers as the company's auditor. The nomination committee's proposal is accessible, in Swedish, on the web page for the annual general meeting 2021 on [www.irlab.se](http://www.irlab.se) under the menu Corporate governance.

### About Martin Nicklasson

Martin Nicklasson, born 1955, has more than 40 years of experience within Life Sciences with about 25 years in executive positions at AstraZeneca and Kabi Pharmacia, e.g. CEO Astra Pain Control AB, CEO Astra Hässle AB and member of AstraZeneca's group management team. He has been the CEO of Biovitrum AB and Sobi AB and has an extensive experience of several boards within the Life Sciences in Sweden, Norway, Denmark, Switzerland and the UK and US.

### For more information

Daniel Johnsson, Chair of the nomination committee

Phone: +46 73 687 64 00

E-mail: daniel.captech@gmail.com

Gunnar Olsson, Chair of the board

Phone: +46 70 576 14 02

E-mail: gunnar.olsson@irlab.se

### About IRLAB

IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson's disease. The company's most advanced candidates, mesdopetam (IRL790) and pirepemate (IRL752), both of which completed Phase IIa studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (The Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB is listed on Nasdaq Stockholm Main Market. More information on [www.irlab.se](http://www.irlab.se).